BioCryst Pharmaceuticals (BCRX) drew fresh attention after reporting fourth quarter 2025 revenue of US$406.56 million and net income of US$245.85 million, compared with revenue of US$131.53 million and a net loss a year earlier.

The earnings swing to profitability has coincided with a 29.26% 1 month share price return and a 14.27% year to date share price return. However, the 5 year total shareholder return of a 37.03% decline shows longer term holders have had a tougher run, suggesting recent momentum is now rebuilding from a weaker base.

If this kind of turnaround story has your attention, it could be a good moment to check out 31 healthcare AI stocks as another way to spot potential opportunities in cutting edge treatments and technologies.

With BioCryst now profitable and the share price up in the short term but still lower over five years, the key question is whether the recent earnings power is underappreciated or whether the market is already pricing in future growth.

Most Popular Narrative: 58.2% Undervalued

The most followed narrative estimates BioCryst Pharmaceuticals' fair value at $20.50 per share, well above the last close of $8.57, and describes current pricing as a significant discount.

Significant financial flexibility from the sale of the European business and accelerated debt paydown positions BioCryst to deploy capital for pipeline advancement, targeted M&A, or in-licensing, which could create additional future revenue streams and support stronger net margins.

Want to see what kind of revenue path, profit margins, and future earnings multiple would need to align for that valuation to make sense? The narrative uses a specific mix of growth assumptions and profitability targets that goes well beyond a simple price target.

Result: Fair Value of $20.50 (UNDERVALUED)

However, this depends on ORLADEYO remaining resilient against rival HAE treatments and on early stage pipeline projects avoiding delays or disappointing clinical and regulatory outcomes.

Next Steps

Does this mix of optimism and caution match how you see BioCryst right now, or does it feel off? Take a closer look at the full balance between potential upside and areas of concern by checking the 4 key rewards and 3 important warning signs and weighing the trade off for yourself.

Looking for more investment ideas?

If you stop here, you could miss other companies that fit your style, so use the screener to line up a watchlist that actually matches your goals.

• Target steady compounders by scanning for companies in the 77 resilient stocks with low risk scores that may suit a more defensive approach to equity investing.
• Spot potential mispricings early by reviewing our screener containing 24 high quality undiscovered gems, built to highlight businesses that are not widely followed yet still have solid fundamentals.
• Prioritise financial strength with the solid balance sheet and fundamentals stocks screener (41 results), helping you focus on companies that pair healthier balance sheets with consistent operating profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.